Dexamethasone and dexmedetomidine as adjuvants to local anesthetic mixture in erector spinae plane block combined with serratus anterior plane block for thoracoscopic surgery: a prospective, randomized controlled trial.

Background: We aimed to investigate the effect of dexamethasone and dexmedetomidine in erector spinae plane block combined with serratus anterior plane block for thoracoscopic postoperative analgesia.

Methods: Ninety-six patients undergoing thoracoscopic surgery were randomly divided into group R (0.375% ropivacaine + saline diluted to 40 mL), group RS (0.

Effect of perioperative intravenous infusion of dexmedetomidine on the quality of early and long-term postoperative recovery in patients undergoing thoracoscopic surgery: a randomized controlled trial.

Background: This study aimed to evaluate the effect of perioperative intravenous infusion of dexmedetomidine on the quality of early and long-term postoperative recovery in patients undergoing thoracoscopic surgery, and to further analyze its potential mechanism.

Methods: A total of 80 patients were enrolled and randomized to dexmedetomidine group, which received perioperative intravenous infusion of dexmedetomidine and normal saline group, which received equivalent doses of normal saline. The primary outcome was total QoR-15 score on postoperative day 1.

Improvement in postoperative pain control by combined use of intravenous dexamethasone with dexmedetomidine after erector spinae plane block and serratus anterior plane block for thoracoscopic surgery: a randomized controlled trial.

Background: Acute pain after thoracoscopic surgery is very noticeable and often requires additional techniques or adjunctive medications to reduce it. We investigated whether intravenous dexamethasone with dexmedetomidine after erector spinae plane block and serratus anterior plane block could further decrease the incidence of moderate-to-severe pain.

Methods: A total of 81 patients were randomly assigned to group C (20 mL normal saline), group S (10 mg dexamethasone + normal saline to 20 mL), or group SM (10 mg dexamethasone + 1 µg/kg dexmedetomidine + normal saline to 20 mL).

Intranasal delivery of macrophage cell membrane cloaked biomimetic drug-nanoparticle system attenuates acute lung injury.

Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), a life-threatening disease, is typically induced by uncontrolled inflammatory responses and excessive production of reactive oxygen species (ROS). Astaxanthin (Ast) is known for its powerful natural antioxidant properties, showcasing excellent antioxidant, anti-inflammatory, and immunomodulatory effects. However, its poor water solubility and bioavailability significantly limit its efficacy.

Inhaled platelet vesicle-decoyed biomimetic nanoparticles attenuate inflammatory lung injury.

Acute lung injury (ALI) is an inflammatory response which causes serious damages to alveolar epithelia and vasculature, and it still remains high lethality and mortality with no effective treatment. Based on the inflammatory homing of platelets and cell membrane cloaking nanotechnology, in this study we developed a biomimetic anti-inflammation nanoparticle delivery system for ALI treatment. PM@Cur-RV NPs were designed by combining the poly (lactic-co-glycolic acid) nanoparticles (NPs) coated with platelet membrane vesicles (PM) for the purpose of highly targeting delivery of curcumin (Cur) and resveratrol (RV) to inflammatory lungs.